Overview
Chris Shorey is an associate in the Mergers & Acquisitions practice at Paul Hastings and is based in the firm's Boston office.
Chris advises public and private companies, financial institutions and investors in a broad range of domestic and cross-border transactional matters, including mergers and acquisitions, divestitures, minority investments and other strategic transactions, as well as advising in other corporate and securities matters, including corporate governance, SEC reporting and general corporate and commercial matters.
Chris has substantial transactional involvement across numerous industries, including healthcare, media and entertainment, technology, consumer products and industrial.
Prior to joining Paul Hastings in 2025, Chris was an associate in the M&A group in the Boston office of another leading global law firm.
Education
- Duke University School of Law, J.D., 2021
- The Fuqua School of Business, M.B.A., 2021
- Colby College, B.A., 2016
Representations
- 908 Devices Inc. in its sale of its portfolio of desktop devices used in the field of bioprocessing process analytical technologies to Repligen Corporation.
- Paratek Pharmaceuticals, Inc. in its sale to Gurnet Point Capital and Novo Holdings.
- Provention Bio in its $2.9 billion sale to Sanofi.
- Signify Health in its sale to CVS Health in an all-cash transaction valued at approximately $8 billion in total consideration.
- America’s Test Kitchen in its sale to Marquee Brands.
- Pfizer Inc. in its $6.7 billion acquisition of Arena Pharmaceuticals, Inc.
Matters may have been completed before joining Paul Hastings.
News
- Paul Hastings Advises Passthrough on Its Sale to iCapital - February 11th, 2026
- Paul Hastings Advises Varonis on Its Acquisition of AllTrue.ai - February 4th, 2026
- Paul Hastings Advises Groq on Its Non-Exclusive Inference Technology Licensing Agreement With Nvidia - December 31st, 2025
- Paul Hastings Advises Heidrick & Struggles in Completed $1.3 Billion Take-Private Transaction - December 11th, 2025
- Paul Hastings Advises Heidrick & Struggles in $1.3 Billion Definitive Agreement With Investor Consortium Led by Advent International and Corvex to Become a Private Company - October 6th, 2025
- Paul Hastings Advises Morgan Stanley in Compass’ $10 Billion Combination With Anywhere Real Estate - September 24th, 2025
- Paul Hastings Advises Varonis in Its Acquisition of SlashNext - September 2nd, 2025
- Paul Hastings Advises Cellebrite in Its Acquisition of Corellium - June 5th, 2025